患者报告鼻窦症状与抗中性粒细胞胞浆抗体相关性血管炎复发风险
这项前瞻性纵向研究纳入168例抗中性粒细胞胞浆抗体相关性血管炎(AAV)患者和51名健康对照,共773次访视,使用22项鼻窦结局测试(SNOT-22)评估鼻窦症状与疾病活动及复发的关系。结果显示,AAV患者缓解期SNOT-22中位数高于对照(20 vs 5,P<0.001),活动期高于缓解期(P<0.001);较高的SNOT-22评分与复发风险增加相关(风险比2.7,95%CI 1.2-6.2;P=0.02)。
要点
- AAV患者缓解期SNOT-22中位数20,高于健康对照的5(P<0.001)。
- AAV活动期SNOT-22高于缓解期(P<0.001)。
- 较高SNOT-22评分与复发风险增加相关(HR 2.7,95%CI 1.2-6.2;P=0.02)。
核心结论
- 患者报告的鼻窦疾病结局指标SNOT-22不仅随AAV疾病活动变化,还与两年内较高的复发风险相关。
- 这些发现支持SNOT-22评分可能增强复发预测,以及持续性鼻窦疾病可能在复发病理生理中具有重要性。
研究设计与样本
- 前瞻性纵向研究,纳入168例AAV患者和51名健康对照,共773次访视(其中106次为活动性疾病访视)。
- 复发定义为Wegner肉芽肿的伯明翰血管炎活动评分>0。
- 使用广义估计方程和Cox比例风险模型评估SNOT-22与复发的关联。
主要发现
- AAV患者缓解期SNOT-22中位数为20,健康对照为5(P<0.001)。
- AAV活动期SNOT-22高于缓解期(P<0.001)。
- 在所有AAV患者中,尤其在肉芽肿性多血管炎中,复发前数月至数年观察到较高的SNOT-22评分,且与复发风险增加相关(风险比2.7,95%置信区间1.2-6.2;P=0.02)。
- 在比较有和无鼻窦疾病的患者以及排除局限于耳鼻喉的复发后,观察到相似结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Relapses are frequent and difficult to predict in antineutrophil cytoplasmic antibody-associated vasculitis (AAV), resulting in long-term use of immunosuppression. Although sinonasal disease is associated with relapse of AAV, detailed characterization of sinonasal symptoms is lacking. Using a patient-reported outcome, the 22-item SinoNasal Outcome Test (SNOT-22), we investigated the relationship between sinonasal symptoms and disease activity in AAV. METHODS: This was a prospective, longitudinal study of individual with AAV and healthy individuals. Relapse was defined as a Birmingham Vasculitis Activity Score for Wegner's Granulomatosis score >0. Higher SNOT-22 scores indicate worse symptoms. Generalized estimating equation and Cox proportional hazard models evaluated the association between SNOT-22 and relapse. RESULTS: There were 773 visits (106 active disease visits) from 168 patients with AAV and 51 controls. Median SNOT-22 at remission was higher in AAV versus controls (20 vs 5; P < 0.001) and higher during active disease versus remission (P < 0.001). In all AAV, and particularly within granulomatosis with polyangiitis, higher SNOT-22 scores were observed months to years before relapse and were associated with increased risk of relapse (hazard ratio 2.7, 95% confidence interval 1.2-6.2; P = 0.02). Similar findings were seen when examining patients with versus without sinonasal disease and after removing relapses limited to the ear, nose, and throat. CONCLUSION: A patient-reported outcome measure of sinonasal disease, the SNOT-22, not only changes with disease activity in AAV, but also is associated with a higher risk of relapse within two years. These findings support the possibility that the SNOT-22 score may enhance prediction of relapse and that persistent sinonasal disease may be important in the pathophysiology of relapse.
引用
- Romich E, Banerjee S, Amudala N, et al. Patient-Reported Sinonasal Symptoms and Risk of Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2024. PMID: 38523260. doi:10.1002/acr.25329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。